{"id":"NCT01128959","sponsor":"Lundbeck LLC","briefTitle":"Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy","officialTitle":"Open-Label Study to Assess the Safety and Tolerability of Intravenous Carbamazepine as Short-Term Replacement of Oral Carbamazepine in Adult Patients With Epilepsy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-06","primaryCompletion":"2013-01","completion":"2013-01","firstPosted":"2010-05-24","resultsPosted":"2016-12-05","lastUpdate":"2018-01-16"},"enrollment":108,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Epilepsy"],"interventions":[{"type":"DRUG","name":"Intravenous Carbamazepine (IV CBZ)","otherNames":[]}],"arms":[{"label":"Intravenous Carbamazepine (IV CBZ)","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to assess the safety and tolerability of intravenous (IV) carbamazepine (CBZ) administered as multiple 15 minute infusions and a single 5 minute infusion to adult patients with epilepsy on stable higher doses of oral CBZ.","primaryOutcome":{"measure":"Adverse Events","timeFrame":"Baseline to after last iv dose on day 4","effectByArm":[{"arm":"Intravenous Carbamazepine (IV CBZ) 15 Minutes Infusion","deltaMin":126,"sd":null},{"arm":"Intravenous Carbamazepine (IV CBZ) 5 Minutes Infusion","deltaMin":26,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":29,"countries":["United States"]},"refs":{"pmids":["25912051"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":105},"commonTop":["Dizziness","Headache","Somnolence"]}}